PD-L1 evaluation in the gastrointestinal tract: from biological rationale to its clinical application

Immune-checkpoint inhibitors targeting the PD-1/PD-L1 axis have brought significant clinical benefit in many solid cancer types, including gastrointestinal malignancies. However, it has been estimated that only 20-40% of patients respond to treatment. The pattern of expression and potential predicti...

Descripción completa

Detalles Bibliográficos
Autores principales: Mastracci, Luca, Grillo, Federica, Parente, Paola, Gullo, Irene, Campora, Michela, Angerilli, Valentina, Rossi, Chiara, Sacramento, Maria Luisa, Pennelli, Gianmaria, Vanoli, Alessandro, Fassan, Matteo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Pacini Editore srl 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9614301/
https://www.ncbi.nlm.nih.gov/pubmed/36305021
http://dx.doi.org/10.32074/1591-951X-803

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9614301/
https://www.ncbi.nlm.nih.gov/pubmed/36305021
http://dx.doi.org/10.32074/1591-951X-803

Ejemplares similares